Rep. Mariannette Miller-Meeks

Maddy summaryHRES 939 is a symbolic House resolution expressing support for designating February 21-25, 2022, as "Public Schools Week." It does not create new policies, allocate funding, or impose requirements on schools or students. The resolution uses supportive language to acknowledge public education's role in democracy but has no legal effect. It was introduced by multiple representatives as a non-binding gesture of appreciation for public schools.

Promoting Ties with Taiwan Act This bill requires the Department of State to submit to Congress a strategy to (1) work with allies and partners to support the expansion of Taiwan's relations and engagement with countries around the world, (2) promote the establishment of Taiwan's presence in countries and partners where Taiwan does not have a permanent presence, and (3) strengthen economic relations and supply chain resilience among Taiwan and like-minded partners to counter threats and malign influences from authoritarian regimes. Within one year of submitting the strategy, the State Department must report to Congress on actions taken to carry out the strategy.

Upholding the 1995 Jerusalem Embassy Law Act of 2021 This bill prohibits using federal funds to establish any diplomatic facility in Jerusalem other than the U.S. Embassy to Israel.

Insulin Savings for Patients Act This bill requires 100% of negotiated price concessions for covered insulin products under the Medicare prescription drug benefit to be reflected at the point of sale by 2024. The Government Accountability Office must annually report on the effects of the bill's implementation, including with respect to insulin prices.

This resolution expresses the sense of the House of Representatives that the International Olympic Committee (IOC) should remove from the International Olympic Committee Executive Board certain countries that are subject to sanctions for human rights violations and bars such countries from participating in the IOC's decision-making processes.

This resolution addresses the need for improvements to broadband infrastructure, particularly in rural areas, and the role of specified federal agencies in making such improvements.

Internal Revenue Service Processing Returns Instead Of Removing Innocent Taxpayers' Income Every Season Act of 2022 or the IRS PRIORITIES Act of 2022 This bill prohibits the Internal Revenue Service from hiring new enforcement personnel (i.e., special agents in the criminal investigation division, revenue officers, or revenue agents) until all individual tax returns for 2019 and 2020 are processed.

This resolution requests the President and directs the Department of Homeland Security (DHS) to transmit to the House of Representatives, no later than 14 days after the date of the adoption of this resolution, copies of certain documents and other materials, both classified and unclassified, in the possession of the President or DHS as of the date of adoption of this resolution that refer or relate to certain aspects on border policy, particularly along the southwestern border.

This bill requires the Food and Drug Administration (FDA) to report to Congress on barriers to the domestic manufacturing of imported active pharmaceutical ingredients, finished drug products, and devices that are critical to public health. The report must recommend strategies to overcome such barriers. The FDA may, to the extent appropriate, implement the strategies.

Safeguarding Women's and Children's Health Act of 2022 This bill imposes reporting requirements relating to abortion drugs. The Food and Drug Administration (FDA) must require health care practitioners to report (1) any death or adverse event associated with the use of an abortion drug, whether or not the adverse event is considered drug-related; and (2) each time the practitioner prescribes, dispenses, or administers such a drug. The FDA must establish online portals for health care practitioners to report such information and for patients to self-report adverse events. The Centers for Disease Control and Prevention must aggregate the collected information and annually publish data about such drugs, including the number of prescriptions and adverse events occurring within 120 days of use.